CareDx, Inc.
Nasdaq · Services-Medical Laboratories
Company Overview
A concise company profile alongside the latest public filing activity.
CareDx develops diagnostic tests and digital services for transplant patients, including blood-based tests that monitor organ rejection in kidney, heart, and lung transplant recipients, along with transplant genomics and patient management software used by transplant centers.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Kennedy KeithCFO & COO | Sell | $2.16M | 28,256at $76.55 | Nov 5, 2026 |
| Kennedy KeithCFO & COO | Sell | $958K | 12,380at $77.42 | Nov 5, 2026 |
| Kennedy KeithCFO & COO | Sell | $542K | 6,897at $78.59 | Nov 5, 2026 |
| Kennedy KeithCFO & COO | Sell | $589K | 7,415at $79.49 | Nov 5, 2026 |
| Kennedy KeithCFO & COO | Sell | $274K | 3,403at $80.38 | Nov 5, 2026 |
| Kennedy KeithCFO & COO | Sell | $221K | 2,710at $81.40 | Nov 5, 2026 |
| Kennedy KeithCFO & COO | Sell | $25K | 300at $82.08 | Nov 5, 2026 |
| Kennedy KeithCFO & COO | Sell | $50K | 600at $83.60 | Nov 5, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable CDNA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.